Shots:

• Lineage to receive a $50M up front and is eligible to receive ~$620M in additional development, approval, and sales milestone along with royalties
• The collaboration will combine Lineage’s cell therapy technology with Genentech’s ophthalmology expertise and capabilities to advance the OpRegen program for serious ocular disorders including dry AMD
• Lineage will be responsible to complete the activities related to the ongoing clinical study and perform manufacturing activities. Genentech will lead the clinical development and commercialization of Lineage’s OpRegen program which is currently being evaluated in a P-I/IIa dose-escalation study for advanced dry AMD with GA

Ref: Businesswire | Image: Lineage